The Business Bytes
New Delhi, October 2, 2024 (TBB Bureau): The Competition Commission of India (CCI) has granted approval for the acquisition of Bharat Serums and Vaccines Limited (BSV) by Mankind Pharma Ltd. This acquisition involves Mankind Pharma securing 100% shareholding in BSV, marking a significant move in the pharmaceutical industry.
Mankind Pharma, a publicly listed entity, is a major player in the pharmaceutical sector, involved in the development, manufacturing, and marketing of a broad spectrum of pharmaceutical finished dosage formulations (FDFs). The company operates across both acute and chronic therapeutic areas. In addition to pharmaceuticals, Mankind has a substantial footprint in the consumer healthcare market, producing popular products such as condoms, emergency contraceptives, pregnancy test kits, vitamins, antacids, and anti-acne preparations.
Moreover, Mankind Pharma, through its subsidiaries, also manufactures and sells active pharmaceutical ingredients (APIs), pharmaceutical intermediates, and packaging products for pharmaceutical purposes. This diverse portfolio has made Mankind a key player in both domestic and international markets.
Bharat Serums and Vaccines Limited (BSV), a renowned name in the healthcare space, is involved in the research, development, licensing, manufacturing, and distribution of a wide range of pharmaceutical products. These include FDFs, APIs, biotech and biological formulations, food and health supplements, medical devices, and ayurvedic medicines. The company specializes in therapeutic areas such as gynecology, in-vitro fertilization (IVF), critical care, and emergency medicine. In India, BSV’s focus has been on developing and marketing biological and biotech products, particularly in women’s health, IVF, and emergency care.
BSV’s wholly owned Indian subsidiary, BSV Pharma Private Limited, which is in the process of merging with BSV, also adds to the company’s strength in these fields.
The acquisition aligns with Mankind Pharma’s strategy to expand its capabilities in key therapeutic areas such as women’s health and critical care, while also increasing its reach in the biotechnology and biological product segments. This move further consolidates Mankind’s position in the healthcare industry, offering a wider range of critical products to the market.
With this acquisition, Mankind Pharma will significantly bolster its presence in both the domestic and global pharmaceutical markets, particularly in specialized fields such as gynecology and emergency medicine. The deal is expected to provide a strong synergy between Mankind’s extensive marketing expertise and BSV’s advanced research and product development capabilities.
